Bone Health Archives - malecare.org

Comparison Evaluating Bone Mineral Density Changes in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

The current standard hormone therapy (ADT) for men with advanced prostate cancer is a class of drugs called Luteinising hormone-releasing hormone agonists (LHRHa). These drugs reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss as a side effect of the ADT. Using transdermal (skin patches) oestradiol is a potential alternative to [...]

By Malecare|2016-04-05T12:04:43-04:00April 5th, 2016|Advanced Prostate Cancer, Bone Health, Bone Mineral Density, Bones and Prostate Cancer, Drugs & Treatments, estrogen patches, Hormone Therapy, Research, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments

What You Need to Know About Xgeva or Denosumab

Xgeva, also known as denosumab, is an injectable medication (injected once a month subcutaneously under the skin in the doctor’s office) that is used to prevent bone fractures and spinal cord compression caused by bone metastases in breast and prostate cancer survivors. Solid tumors in the bone, which is a common site for individuals with [...]

By Malecare|2020-02-04T11:24:25-05:00September 18th, 2015|Advanced Prostate Cancer, bisphosphonates, Bone Health, Bone Metastases, Bones and Prostate Cancer, denosumab - Prolia, denosumab - Xgeva, Drugs & Treatments, Uncategorized, Xgeva|0 Comments

Skeletal Events and the Treatment of Men with Advanced Prostate Cancer

Many of our doctors are constantly vigilant about our developing skeletal related issues. Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]

By Malecare|2015-07-07T15:24:33-04:00July 7th, 2015|Advanced Prostate Cancer, Alpharadin (radium-223), bisphosphonates, Bone Health, Bone Metastases, Bones and Prostate Cancer, denosumab - Xgeva, Drugs & Treatments, enzalutamide, radiopharmaceuticals, Uncategorized, Xofigo, Xtandi, Zometa, Zytiga|0 Comments

It Maybe Time To Change The Dosing Schedule Of Zoledronic Acid To Every 12 Weeks

In a presentation at the ASCO Annual Meeting, Dr. Andrew Himelstein, MD, FACP of the Helen F. Graham Cancer Center & Research Institute, presented the results of a trial evaluating Zoledronic Acid (Zometa) at a dosing schedule of every 12 weeks as opposed to the current standard of care of every 4 weeks. The trial included [...]

By Malecare|2020-02-04T11:54:43-05:00June 4th, 2015|Advanced Prostate Cancer, ASCO, bisphosphonates, Bone Health, Bone Metastases, Bones and Prostate Cancer, Clinical Trials, Drugs & Treatments, Uncategorized, Zometa|0 Comments

Understanding the Complexities of Bone Metastases in Prostate Cancer

Our bones operate in a balanced and dynamic system, which in the normal situation keep them strong. Bones are constantly being eliminated and then remade to keep them healthy and read to support our frame. This normal process involves two major kinds of bone cells that work together, in balance, to keep bones healthy and [...]

By Malecare|2017-10-19T10:47:31-04:00February 6th, 2015|Advanced Prostate Cancer, Bone Health, Bone Metastases, Uncategorized, Understanding APC|2 Comments

Radiologic Progression Free Survival Might Predict Treatment Response and Survival

In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan [...]

By Malecare|2017-10-19T10:47:35-04:00January 28th, 2015|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Bone Health, Bone Metastases, Clinical Trials, Clinical Trials, DOD, Drugs & Treatments, General Information, survival, Uncategorized, Understanding APC, Zytiga|0 Comments

Bone Complications Among Prostate Cancer Survivors Having Prolonged Hormone Therapy (ADT)

Androgen deprivation therapy (ADT) and bone complications are the two near universals for men with advanced prostate cancer. A long-term follow up of fifteen (15) years after diagnosis of a population-based cohort of prostate cancer survivors proved to be very informative. The Prostate Cancer Outcomes Study, which enrolled 3533 men diagnosed with prostate cancer between [...]

By Malecare|2020-02-04T08:42:24-05:00November 12th, 2014|ADT, Advanced Prostate Cancer, Bone Health, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

Randy Sheffield Shares An Important Warning About ONJ

Randy Sheffield, a member of the Malecare Advanced Prostate Cancer Online support group recently has had his fight with advanced prostate cancer made even more complex when he developed Osteonecrosis of the jaw (ONJ). ONJ is an uncommon but terrible side effect of taking bisphosphonates. Randy wrote a warning to all the members of the [...]

By Malecare|2020-02-04T08:42:16-05:00October 1st, 2014|Advanced Prostate Cancer, bisphosphonates, Bone Health, Bone Mineral Density, Drugs & Treatments, General Information, Guest Bloggers, Quality of Life, Uncategorized, Understanding APC, Zometa|0 Comments

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

By Malecare|2017-10-19T10:47:58-04:00September 30th, 2014|2nd line hormone therapy, abiraterone acetate, adjuvant therapy, ADT, Advanced Prostate Cancer, Alpha Emitting Radio Therapy, Alpharadin (radium-223), Androgan Receptor Inhibitor, Bio Chemical Recurrence, biomarkers, bisphosphonates, Bone Health, Bone Metastases, Bone Mineral Density, CAB, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Combination Therapy, Cross Resistance, Cryotherapy, CTCs, denosumab - Xgeva, Diet, Diet and Supplements, Drugs & Treatments, Early Access Program (EAP), Early/Expanded Access Programs, End-Of-Life, enzalutamide, estrogen patches, FDA, Financial, Firmagon (degarelix), General Information, genetics, HIFU, Hormone Therapy, Hot Flashes, How We Live, immunotherapy, Incontinence, inflammation, ipilimumab, ketoconazole, Medicare/Medicaid, mental health, Metastases, MRIs, NCI, neuroendocrine prostate cancer, neutropenia, Nilandron, oligometastic, On The Horizon, Our Caretakers, Pain, perineural invasion, peripheral neuropathy, Personal Experiences, prognostic tools, Prostate Ponderings, Prostvac, Provenge, PSA, PSADT, Quality of Life, radiation proctitis, radiopharmaceuticals, Radiotherapy, Research, Revlimid (lenalidomide), salvage therapy, statins, supplements, survival, survivorship, TAK700, teleconferences, Uncategorized, Understanding APC, vaccines, Vitamine D3, weight gain, Xgeva, XL184, Xofigo, Xtandi, Zometa, Zytiga|1 Comment

Bone Metastases and Prostate Cancer

The vast majority of men with advanced prostate cancer will eventually develop bone metastases. Given this fact it is important to understand what is meant by the term bone metastases. Bones serve as the supporting framework of our bodies. Like the rest of us bones are constructed of cells. These cells compose a network or [...]